<DOC>
	<DOCNO>NCT01530841</DOCNO>
	<brief_summary>Myotonic dystrophy type 1 myopathy complex respiratory pattern risk develop respiratory failure . Classical mode ventilation sometimes tolerate ineffective population . New modes nocturnal ventilation combine volumetric barometric advantage . The aim study compare effect AVAPS mode bilevel pressure support .</brief_summary>
	<brief_title>Efficacy Tolerance AVAPS Mode Myotonic Dystrophy</brief_title>
	<detailed_description>Justification study Respiratory abnormality complex Myotonic dystrophy type 1 . Some patient present isolated alveolar hypoventilation breathe rhythm irregularity . Nocturnal ventilation usually propose usual mode ventilation ca n't provide enough respiratory assistance patient especially REM sleep much respiratory assistance increase risk asynchrony . The goal study evaluate effect mode AVAPS ( mode permit pressure support guarantee volume offer advantage volume pressure support Bipap A30 Phillips Respironics ) compare bilevel pressure support . Main Objective To evaluate efficacy AVAPS Mode day 7 arterial PCO2 ventilation launch ventilation . Secondary Objectives To evaluate efficacy AVAPS Mode day 90 daytime arterial PCO2 launch ventilation . To evaluate compliance ventilation day 7 90 . To evaluate clinical efficacy respiratory symptom , dyspnea sleepiness day 1 90 . To evaluate quality life day 1 90 . To evaluate effect AVAPS polysomnography , nocturnal SaO2 , nocturnal PtCO2 . To evaluate Multiple sleep latency Maintenance wakefulness test day 90 . To evaluate effect AVAPS respiratory parameter VC mouth maximal pressure . Type study : Prospective , monocentre , randomize , control single blind study 2 parallel group . Number subject : 32 patient recruit home ventilation unit Raymond Poincar√© hospital . Selection criterion : Patients Myotonic dystrophy present least one clinical sign : effort rest dyspnea , orthopnea , sleepiness , morning headache VC &lt; 50 % Pi max &lt; 60 cm H2O time SaO2 &lt; 90 % 5 minute Hypercapnia &gt; 6.0 kPa . Study process Preceding screen period within 3 month inclusion . Day 1 day 3 baseline evaluation . Day 3 Inclusion Randomisation Day 3 8 Launch ventilation Day 8 Home discharge Day 90 Evaluation efficacy ( secondary objective ) observance . Duration Participation patient 3 month . Period inclusion 24 month . Total duration study 30 month .</detailed_description>
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<criteria>Men woman age &gt; 18 year Written consent DM1 myotonic dystrophy One clinical sign dyspnea rest/effort , orthopnea , daytime sleepiness ( Epworth &gt; 10 ) , morning headache . Or restrictive syndrome : VC &lt; 50 % Pi max &lt; 60 cm H2O Or time nocturnal saturation &lt; 90 % , &gt; 5 minute . AND Hypercapnia &gt; 6.0 kPa Pregnancy test negative use contraception woman age procreation Patient use previously home ventilation within 6 month enter study Patient deny home ventilation Refusal sign consent impossibility follow 3 month Impossibility apply ventilation home No social/health coverage Patient tutelage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myotonic dystrophy type 1</keyword>
	<keyword>Home ventilation</keyword>
	<keyword>Respiratory insufficiency</keyword>
	<keyword>Neuromuscular</keyword>
</DOC>